Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: BMS is a global pharmaceutical and healthcare company organized into three reportable segments: Pharmaceuticals (80% of sales), Nutritionals (10% of sales), and Other Healthcare (10% of sales). The company focuses on ten critical disease areas, including cardiovascular, virology, oncology, and diabetes. In 2004, the company committed to selling its Oncology Therapeutics Network (OTN) business, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | 2004 | 2003 | Change |
|---|---|---|---|
| Net Sales | $19,380 million | $18,653 million | +4% |
| Earnings from Continuing Operations | $2,378 million | $3,097 million | -23% |
| Net Earnings | $2,388 million | $3,106 million | -23% |
| Diluted EPS (Continuing Ops) | $1.21 | $1.59 | -24% |
| Operating Cash Flow | $3,176 million | $3,512 million | -10% |
| Long-Term Debt | $8,463 million | $8,522 million | Flat |
| Cash & Cash Equivalents | $3,680 million | $2,549 million | +44% |
| Working Capital | $4,958 million | $4,536 million | +9% |
Margins: Gross margin decreased to 69.1% in 2004 from 71.0% in 2003, primarily due to product mix changes and generic competition. The effective income tax rate increased to 34.4% in 2004 from 25.8% in 2003, largely driven by a $575 million charge for deferred taxes related to the repatriation of foreign earnings under the American Jobs Creation Act.
Material Changes vs. Prior Period
- Revenue Drivers: Sales growth was driven by foreign exchange rates (+4% impact) and strong performance of key brands like PLAVIX* (+35% to $3.3 billion) and AVAPRO*/AVALIDE* (+23%). This was offset by significant declines in products losing market exclusivity, including PRAVACHOL (-7%), MONOPRIL (-42%), and the GLUCOPHAGE* franchise (-65%).
- Profitability Decline: Earnings from continuing operations dropped 23% due to increased litigation charges ($420 million vs. $199 million in 2003), higher R&D spending ($2.5 billion vs. $2.3 billion), and the aforementioned gross margin erosion.
- Divestitures: The company completed the sale of its Adult Nutritional business to Novartis in February 2004, recording a pre-tax gain of $320 million. It also announced plans to divest its U.S. and Canadian Consumer Medicines business in January 2005.
- Acquisitions: Acquired Acordis Speciality Fibres for $150 million to strengthen its wound therapeutics portfolio.
Guidance, Outlook, and Risks
Outlook: Management anticipates substantial incremental revenue losses in 2005, 2006, and 2007 due to the expiration of market exclusivity for key products. For 2005 alone, the company estimates net sales reductions of $1.4 billion to $1.5 billion compared to 2004 levels. Earnings growth is not expected to resume until 2007, contingent on the success of new product launches and the offsetting of exclusivity losses.
Key Risks and Contingencies:
- Patent Litigation: The composition of matter patent for PLAVIX* (the company's largest product) is subject to litigation. An adverse outcome could lead to generic competition as early as the second half of 2005, which would be material to financial condition and liquidity.
- Legal Proceedings: The company faces significant pending lawsuits regarding wholesaler inventory practices, pricing, and product liability (e.g., SERZONE, PPA). Management believes the aggregate impact beyond current reserves is reasonably likely to be material to results of operations.
- Regulatory Environment: The company is subject to extensive government regulation regarding pricing, reimbursement, and manufacturing. The Medicare Prescription Drug Improvement and Modernization Act (MMA) has already negatively impacted U.S. oncology business reimbursement levels.
- SEC Consent Order: In August 2004, the company settled an SEC investigation regarding wholesaler inventory and accounting matters, agreeing to a $150 million fund for shareholders and implementing strict controls on sales to direct customers.
Investor Verification Checklist
- PLAVIX* Litigation Status: Verify the current status of the patent infringement lawsuits in the U.S. and Canada, as the outcome directly impacts the company's largest revenue stream.
- Exclusivity Loss Timeline: Confirm the specific dates and projected sales declines for PRAVACHOL (U.S. exclusivity April 2006) and other key products losing protection in 2005-2006.
- Legal Reserves Adequacy: Review the sufficiency of the $486 million reserve for wholesaler inventory/accounting matters and the $134 million reserve for pricing/sales practices litigation.
- Foreign Earnings Repatriation: Assess the impact of the $575 million tax charge related to the American Jobs Creation Act and the company's ability to meet the reinvestment requirements for the tax deduction.
- Divestiture Progress: Monitor the completion of the OTN sale and the planned divestiture of the U.S./Canadian Consumer Medicines business.